# $kod

Kodiak Sciences' Tarcocimab (KSI-301) is entering Phase [--] trials for Non-proliferative Diabetic Retinopathy, a key catalyst for Q1 [----]. However, market sentiment is cautious due to low volumes and potential institutional accumulation.

### About $kod
Kodiak Sciences is a biotechnology company developing novel therapies.  

### Insights
- $kod posts created is up 100% from the previous week.

### Engagements: [-----] (24h)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/t:$kod/c:line/m:interactions/iv:1d.svg)  
[Engagements 24-Hour Time-Series Raw Data](/topic/$kod/time-series/interactions.tsv)  
Current Value: [-----]  
Daily Average: [-----]  
[--] Week: [-----] -20%  
[--] Month: [-------] -42%  
[--] Months: [---------] +133%  
[--] Year: [---------] +85%  
1-Year High: [------] on 2025-03-15  
1-Year Low: [--] on 2025-10-09  

Engagements by network (24h):
YouTube: [--]
Reddit: [--]
X: [-----]

  
  
### Mentions: [--] (24h)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/t:$kod/c:line/m:posts_active/iv:1d.svg)  
[Mentions 24-Hour Time-Series Raw Data](/topic/$kod/time-series/posts_active.tsv)  
Current Value: [--]  
Daily Average: [--]  
1-Year High: [---] on 2025-06-28  
1-Year Low: [--] on 2025-04-09  

Mentions by network (24h):
YouTube: [--]
Reddit: [--]
X: [--]

  
  
### Creators: [--] (24h)
![Creators Line Chart](https://lunarcrush.com/gi/w:600/t:$kod/c:line/m:contributors_active/iv:1d.svg)  
[Creators 24-Hour Time-Series Raw Data](/topic/$kod/time-series/contributors_active.tsv)  
[--] unique social accounts have posts mentioning $kod in the last [--] hours which is down 13% from [--] in the previous [--] hours
Daily Average: [--]  
1-Year High: [---] on 2025-06-28  
1-Year Low: [--] on 2025-04-09  

The most influential creators that mention $kod in the last [--] hours

| Creator                                          | Rank | Followers | Posts | Engagements |
| -------                                          | ---- | --------- | ----- | ----------- |
| [@dresscodecrew](/creator/youtube/dresscodecrew) | [--]    | [-------]   | [--]     | [-------]     |
| [@BiopharmIQ](/creator/twitter/BiopharmIQ)       | [--]    | [------]    | [--]     | [-----]       |
| [@BOSSTRADING0](/creator/twitter/BOSSTRADING0)   | [--]    | [-----]     | [--]     | [---]         |
| [@Brad_E_Schulz](/creator/twitter/Brad_E_Schulz) | [--]    | [------]    | [--]     | [--]          |
| [@SteveDJacobs](/creator/twitter/SteveDJacobs)   | [--]    | [------]    | [--]     | [--]          |

[View More](/list/creators/$kod/100)
  
  
### Sentiment: 100%
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:$kod/c:line/m:sentiment/iv:1d.svg)  
[Sentiment 24-Hour Time-Series Raw Data](/topic/$kod/time-series/sentiment.tsv)  
Current Value: 100%  
Daily Average: 87%  
[--] Week: 100% no change  
[--] Month: 100% +18%  
[--] Months: 100% +33%  
[--] Year: 100% no change  
1-Year High: 100% on 2025-02-13  
1-Year Low: 29% on 2025-11-29  

Most Supportive Themes:
- Phase [--] Trials: (33%) Kodiak Sciences is advancing its Tarcocimab (KSI-301) therapy into Phase [--] trials for Non-proliferative Diabetic Retinopathy.
- Biotech Stock Catalysts: (33%) Kodiak Sciences is listed among several biotech companies with upcoming Phase 2b and Phase [--] readouts in Q1 2026, indicating potential catalysts.
  
Most Critical Themes:
- Market Sentiment and Volume: (33%) Concerns exist about 'death by [----] cuts' and institutions potentially accumulating shares on low volumes, suggesting cautious market sentiment.
  

### Top $kod Social Posts
Top posts by engagements in the last [--] hours

*Showing a maximum of [--] top social posts without a LunarCrush subscription.*

"#KOD $KOD Purple line [--] day MA Green line [--] day MA [--] Blue lines gaps to be filled Death by [----] cuts since BOY 2026.we'll see if the science has anything to say about that when the trials read out. Institutions likely soaking up the last of the shares on anemic volumes"  
[X Link](https://x.com/PG_coffeed/status/2019480319791964355) [@PG_coffeed](/creator/x/PG_coffeed) 2026-02-05T18:36Z [--] followers, [---] engagements


"Biotech Stock Catalyst Watchlist Ph2 & Ph3 readouts in Q1 [----] 📈 $KOD Phase 2b $MDNAF Phase 2b $GOSS Phase [--] $BFRI Phase [--] $BFRI Phase [--] $KPTI Phase [--] $IOVA Phase [--] $AGIO Phase 2b $AVBP Phase [--] $ATAI Phase [--] $MLYS Phase [--] $TARA Phase [--] $CADL Phase 2a $ANRO Phase [--] $IMMP Phase [--] $PEPG Phase [--] $TBPH Phase [--] $CLDX Phase [--] $NVCR Phase [--] $VRDN Phase [--] $CMPX Phase 2/3 $ZBIO Phase [--] $IDYA Phase 2/3 $VXRT Phase 2b $OCUL Phase [--] $LSTA Phase 2b $PCSA Phase [--] $MLTX Phase [--] $OCGN Phase [--] $APGE Phase [--] $CMPS Phase [--] $MBRX Phase [--] $KOD Phase [--] $NKTR Phase 2b $ALZN Phase [--] $HELP Phase [--] $PVLA Phase [--] $ARQT"  
[X Link](https://x.com/BiopharmIQ/status/2018051066605220000) [@BiopharmIQ](/creator/x/BiopharmIQ) 2026-02-01T19:57Z 28.9K followers, 113K engagements


"6 Stocks Likely to Move Big in Q1 [--] See 🧵 for more details about each asset/readout: $RGNX (February [--] 2026) Clemidsogene lanparvovec (RGX-121) / Hunter syndrome (MPS II) / PDUFA $RCKT (March [--] 2026) KRESLADI (RP-L201) / Severe LAD-I / PDUFA $UPB (Q1 2026) Verekitug / Severe asthma / Phase [--] $IMMP (Q1 2026) Eftilagimod alfa (efti) + Keytruda / 1L NSCLC) / Phase [--] $KOD (Q1 2026) Tarcocimab (KSI-301) / Non-proliferative DR / Phase [--] $APGE (Q1 2026) APG777 / Atopic dermatitis / Phase [--] 1/7 https://twitter.com/i/web/status/2012295963503902944 https://twitter.com/i/web/status/2012295963503902944"  
[X Link](https://x.com/BiopharmIQ/status/2012295963503902944) [@BiopharmIQ](/creator/x/BiopharmIQ) 2026-01-16T22:48Z 28.9K followers, 111.2K engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing